Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study

Cancer Treat Rep. 1980;64(12):1387-8.

Abstract

Fifteen patients with metastatic renal cell carcinoma were treated with Baker's antifol at a dose schedule of 250 mg/m2 iv for 3 days every 3 weeks. One objective response was seen, and toxicity was minimal. No usefulness of Baker's antifol in the treatment of metastatic renal cell carcinoma was demonstrated.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Diarrhea / chemically induced
  • Drug Evaluation
  • Female
  • Granulocytes
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Leukocyte Count
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Platelet Count
  • Triazines / adverse effects
  • Triazines / therapeutic use*
  • Vomiting / chemically induced

Substances

  • Triazines
  • triazinate